202 related articles for article (PubMed ID: 28730752)
1. Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in Ldlr
Yu M; Amengual J; Menon A; Kamaly N; Zhou F; Xu X; Saw PE; Lee SJ; Si K; Ortega CA; Choi WI; Lee IH; Bdour Y; Shi J; Mahmoudi M; Jon S; Fisher EA; Farokhzad OC
Adv Healthc Mater; 2017 Oct; 6(20):. PubMed ID: 28730752
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis.
Zhang XQ; Even-Or O; Xu X; van Rosmalen M; Lim L; Gadde S; Farokhzad OC; Fisher EA
Adv Healthc Mater; 2015 Jan; 4(2):228-36. PubMed ID: 25156796
[TBL] [Abstract][Full Text] [Related]
3. Activation of liver X receptor decreases atherosclerosis in Ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells.
Kappus MS; Murphy AJ; Abramowicz S; Ntonga V; Welch CL; Tall AR; Westerterp M
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):279-84. PubMed ID: 24311381
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Redox-Responsive LXR-Activating Nanoparticle Formulations in Primary Mouse Macrophages.
Smith TKT; Kahiel Z; LeBlond ND; Ghorbani P; Farah E; Al-Awosi R; Cote M; Gadde S; Fullerton MD
Molecules; 2019 Oct; 24(20):. PubMed ID: 31635211
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo.
Naik SU; Wang X; Da Silva JS; Jaye M; Macphee CH; Reilly MP; Billheimer JT; Rothblat GH; Rader DJ
Circulation; 2006 Jan; 113(1):90-7. PubMed ID: 16365197
[TBL] [Abstract][Full Text] [Related]
6. Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels.
van der Hoorn J; Lindén D; Lindahl U; Bekkers M; Voskuilen M; Nilsson R; Oscarsson J; Lindstedt E; Princen H
Br J Pharmacol; 2011 Apr; 162(7):1553-63. PubMed ID: 21175581
[TBL] [Abstract][Full Text] [Related]
7. Development of therapeutic polymeric nanoparticles for the resolution of inflammation.
Gadde S; Even-Or O; Kamaly N; Hasija A; Gagnon PG; Adusumilli KH; Erakovic A; Pal AK; Zhang XQ; Kolishetti N; Shi J; Fisher EA; Farokhzad OC
Adv Healthc Mater; 2014 Sep; 3(9):1448-1456. PubMed ID: 24659608
[TBL] [Abstract][Full Text] [Related]
8. Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model.
Briand F; Tréguier M; André A; Grillot D; Issandou M; Ouguerram K; Sulpice T
J Lipid Res; 2010 Apr; 51(4):763-70. PubMed ID: 19965597
[TBL] [Abstract][Full Text] [Related]
9. Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo.
Yasuda T; Grillot D; Billheimer JT; Briand F; Delerive P; Huet S; Rader DJ
Arterioscler Thromb Vasc Biol; 2010 Apr; 30(4):781-6. PubMed ID: 20110577
[TBL] [Abstract][Full Text] [Related]
10. Complement Receptor Targeted Liposomes Encapsulating the Liver X Receptor Agonist GW3965 Accumulate in and Stabilize Atherosclerotic Plaques.
Benne N; Martins Cardoso R; Boyle AL; Kros A; Jiskoot W; Kuiper J; Bouwstra J; Van Eck M; Slütter B
Adv Healthc Mater; 2020 May; 9(10):e2000043. PubMed ID: 32329226
[TBL] [Abstract][Full Text] [Related]
11. The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions.
Laffitte BA; Joseph SB; Chen M; Castrillo A; Repa J; Wilpitz D; Mangelsdorf D; Tontonoz P
Mol Cell Biol; 2003 Mar; 23(6):2182-91. PubMed ID: 12612088
[TBL] [Abstract][Full Text] [Related]
12. Synthetic High-Density Lipoprotein-Mediated Targeted Delivery of Liver X Receptors Agonist Promotes Atherosclerosis Regression.
Guo Y; Yuan W; Yu B; Kuai R; Hu W; Morin EE; Garcia-Barrio MT; Zhang J; Moon JJ; Schwendeman A; Eugene Chen Y
EBioMedicine; 2018 Feb; 28():225-233. PubMed ID: 29361501
[TBL] [Abstract][Full Text] [Related]
13. LXR Agonist T0901317's Hepatic Impact Overrules Its Atheroprotective Action in Macrophages, Driving Early Atherogenesis in Chow-Diet-Fed Male Apolipoprotein E Knockout Mice.
Hoekstra M; de Jong LM; van der Geest R; de Leeuw LR; Krisnamurthi R; Geerling JJ; Van Eck M
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672446
[TBL] [Abstract][Full Text] [Related]
14. The secretome of liver X receptor agonist-treated early outgrowth cells decreases atherosclerosis in Ldlr-/- mice.
Rasheed A; Shawky SA; Tsai R; Jung RG; Simard T; Saikali MF; Hibbert B; Rayner KJ; Cummins CL
Stem Cells Transl Med; 2021 Mar; 10(3):479-491. PubMed ID: 33231376
[TBL] [Abstract][Full Text] [Related]
15. Lipidomic analysis of human primary hepatocytes following LXR activation with GW3965 identifies AGXT2L1 as a main target associated to changes in phosphatidylethanolamine.
Santinha D; Klopot A; Marques I; Ellis E; Jorns C; Johansson H; Melo T; Antonson P; Jakobsson T; Félix V; Gustafsson JÅ; Domingues MR; Mode A; Helguero LA
J Steroid Biochem Mol Biol; 2020 Apr; 198():105558. PubMed ID: 31783151
[TBL] [Abstract][Full Text] [Related]
16. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
Yan W; Zhang T; Cheng J; Zhou X; Qu X; Hu H
Pharmacology; 2010; 86(5-6):306-12. PubMed ID: 21071998
[TBL] [Abstract][Full Text] [Related]
17. A novel potent synthetic steroidal liver X receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR(-/-) mice.
Peng D; Hiipakka RA; Xie JT; Dai Q; Kokontis JM; Reardon CA; Getz GS; Liao S
Br J Pharmacol; 2011 Apr; 162(8):1792-804. PubMed ID: 21232031
[TBL] [Abstract][Full Text] [Related]
18. The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease.
Fessler MB
Pharmacol Ther; 2018 Jan; 181():1-12. PubMed ID: 28720427
[TBL] [Abstract][Full Text] [Related]
19. Suppression of chronic damage in renal allografts by Liver X receptor (LXR) activation relevant contribution of macrophage LXRα.
Kiss E; Popovic Z; Bedke J; Wang S; Bonrouhi M; Gretz N; Stettner P; Teupser D; Thiery J; Porubsky S; Adams J; Gröne HJ
Am J Pathol; 2011 Jul; 179(1):92-103. PubMed ID: 21703396
[TBL] [Abstract][Full Text] [Related]
20. Effect of macrophage overexpression of murine liver X receptor-alpha (LXR-alpha) on atherosclerosis in LDL-receptor deficient mice.
Teupser D; Kretzschmar D; Tennert C; Burkhardt R; Wilfert W; Fengler D; Naumann R; Sippel AE; Thiery J
Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2009-15. PubMed ID: 18787185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
